Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090024 · ClinicalTrials.gov registry record · Phase 2
Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01090024 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 108 participants.
The verdict
NCT01090024, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
Interventions
- DRUG Placebo
- DRUG BI 671800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-03-01 |
| Est. Completion | 2011-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090024
The ClinicalTrials.gov registry entry for NCT01090024 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01090024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090024 about?
NCT01090024 is a clinical study titled "Bi 671800 in Asthmatic Patients on Inhaled Corticosteroids". To investigate the effectiveness and safety of BI 671800 given in the morning (AM), evening (PM) or twice daily (b.i.d.) compared too placebo as add on therapy to inhaled corticosteroid in symptomatic asthma patients.
What is the current status of trial NCT01090024?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2010-03-01. Estimated completion is 2011-02-18.
What interventions are being tested in trial NCT01090024?
The interventions under investigation include: Placebo (DRUG), BI 671800 (DRUG).
Who is sponsoring clinical trial NCT01090024?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.